Selected Publications

• Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis.Singh K, Valido K, Swallow M, Okifo KO, Wang A, Cohen JM, Damsky W. J Am Acad Dermatol. 2023 May; 2023 Feb 11. PMID: 36780951.
• Patient perspectives on the lived experience of granuloma annulare.Clark A, Murphy MJ, King B, Cohen JM, Rosenbach M, Barbieri J, Damsky W. Br J Dermatol. 2023 Jan 23. PMID: 36689498.
• Innate type 2 immunity controls hair follicle commensalism by Demodex mites.Ricardo-Gonzalez RR, Kotas ME, O'Leary CE, Singh K, Damsky W, Liao C, Arouge E, Tenvooren I, Marquez DM, Schroeder AW, Cohen JN, Fassett MS, Lee J, Daniel SG, Bittinger K, Díaz RE, Fraser JS, Ali N, Ansel KM, Spitzer MH, Liang HE, Locksley RM. Immunity. 2022 Oct 11; 2022 Aug 30. PMID: 36044899.
• Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.Damsky W, Wang A, Kim DJ, Young BD, Singh K, Murphy MJ, Daccache J, Clark A, Ayasun R, Ryu C, McGeary MK, Odell ID, Fazzone-Chettiar R, Pucar D, Homer R, Gulati M, Miller EJ, Bosenberg M, Flavell RA, King B. Nat Commun. 2022 Jun 6; 2022 Jun 6. PMID: 35668129.
• Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis.Murphy MJ, Cohen JM, Vesely MD, Damsky W. J Am Acad Dermatol. 2022 May; 2020 Dec 8. PMID: 33307146.
• Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis.Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, Damsky W. JAMA Dermatol. 2021 Dec 1. PMID: 34757416.
• KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. Nature. 2021 Oct; 2021 Oct 20. PMID: 34671158.
• Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis.Wang A, Fogel AL, Murphy MJ, Panse G, McGeary MK, McNiff JM, Bosenberg M, Vesely MD, Cohen JM, Ko CJ, King BA, Damsky W. JID Innov. 2021 Jun; 2021 May 7. PMID: 34909719.
• Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib.Wang A, Rahman NT, McGeary MK, Murphy M, McHenry A, Peterson D, Bosenberg M, Flavell RA, King B, Damsky W. J Allergy Clin Immunol. 2021 May; 2020 Dec 11. PMID: 33317858.
• The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. J Allergy Clin Immunol. 2021 Mar; 2020 Oct 28. PMID: 33129886.
• Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy.Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, Leventhal J, Damsky W. JAAD Case Rep. 2021 Jan; 2020 Dec 1. PMID: 33426249.
• Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis.Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W. J Eur Acad Dermatol Venereol. 2020 Oct; 2020 May 19. PMID: 32277505.
• IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM. Nature. 2020 Jul; 2020 Jun 24. PMID: 32581358.
• Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea.Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. J Invest Dermatol. 2020 Jul; 2020 Jan 16. PMID: 31954727.
• Treatment of severe lichen planus with the JAK inhibitor tofacitinib.Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. J Allergy Clin Immunol. 2020 Jun; 2020 Feb 1. PMID: 32018031.
• The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.Wang A, Singh K, Ibrahim W, King B, Damsky W. Yale J Biol Med. 2020 Mar; 2020 Mar 27. PMID: 32226347.
• Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. J Am Acad Dermatol. 2020 Mar; 2019 Jun 8. PMID: 31185230.
• Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid.Damsky W, Singh K, Galan A, King B. JAAD Case Rep. 2020 Feb; 2020 Jan 24. PMID: 32021895.
• Treatment of granuloma annulare with tofacitinib 2% ointment.Damsky W, King BA. JAAD Case Rep. 2020 Jan; 2019 Dec 30. PMID: 31909145.
• Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib.Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, Ahmad T, King B. JAAD Case Rep. 2019 Dec; 2019 Nov 13. PMID: 31763425.
• Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.Damsky W, Thakral D, Emeagwali N, Galan A, King B. N Engl J Med. 2018 Dec 27. PMID: 30586518.
• T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE. Sci Transl Med. 2018 Apr 11. PMID: 29643229.
• JAK inhibitors in dermatology: The promise of a new drug class.Damsky W, King BA. J Am Acad Dermatol. 2017 Apr; 2017 Jan 28. PMID: 28139263.
• Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib.Damsky W, King BA. JAAD Case Rep. 2016 Nov; 2016 Dec 7. PMID: 28004029.
• Development of bullous pemphigoid during nivolumab therapy.Damsky W, Kole L, Tomayko MM. JAAD Case Rep. 2016 Nov; 2016 Dec 3. PMID: 27981213.
• DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. Cell Rep. 2016 Mar 8; 2016 Feb 25. PMID: 26923591.
• mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. Cancer Cell. 2015 Jan 12. PMID: 25584893.
• β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. Cancer Cell. 2011 Dec 13. PMID: 22172720.
• Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. Nat Genet. 2009 May; 2009 Mar 12. PMID: 19282848.